Durchbruchschmerzen und kurz wirksame Opioide

作者: T. Beutlhauser , J. Oeltjenbruns , M. Schäfer

DOI: 10.1007/S00101-013-2193-7

关键词:

摘要: Conventional opioid therapy consists of the regular administration extended-release opioids following fixed time intervals and, as needed, supplemental use an immediate-release formulation. For patient needs such rescue medication, recent studies distinguished different scenarios, inadequate daily dose or interval (end-of-dose failure) from so-called breakthrough pain where attacks can suddenly occur either spontaneously (idiopathic pain) due to certain provocations (incident despite optimal adjustment. In line with this course, a fast and short-lasting elevation plasma concentration seems be reasonable. Although in European survey majority cancer patients were sufficiently treated opioids, currently running clinical trials examine whether application transmucosal intranasal fentanyl their known reduced maximum concentrations show possible advantage comparison opioids. these intensity number episodes significantly fentanyl; however, magnitude effects does not convincingly appear clinically relevant. Among other reasons may related fact that those who would perhaps benefit treatment have yet been identified.

参考文章(46)
Frank Petzke, Lukas Radbruch, Detlev Zech, Georg Loick, Stefan Grond, Temporal Presentation of Chronic Cancer Pain: Transitory Pains on Admission to a Multidisciplinary Pain Clinic Journal of Pain and Symptom Management. ,vol. 17, pp. 391- 401 ,(1999) , 10.1016/S0885-3924(99)00023-8
P. Felleiter, B. Gustorff, P. Lierz, S. Hornykewycz, H. G. Kress, Use of the World Health Organization guidelines on cancer pain relief before referral to a specialized pain service Schmerz. ,vol. 19, pp. 265- 271 ,(2005) , 10.1007/S00482-004-0338-Y
Active Supportive Care, Cancer pain relief and palliative care : report of a WHO Expert Committee World Health Organization. ,(1990)
Russell K. Portenoy, Neil A. Hagen, Breakthrough pain: definition, prevalence and characteristics Pain. ,vol. 41, pp. 273- 281 ,(1990) , 10.1016/0304-3959(90)90004-W
Jörn Lötsch, Pharmacokinetic–Pharmacodynamic Modeling of Opioids Journal of Pain and Symptom Management. ,vol. 29, pp. 90- 103 ,(2005) , 10.1016/J.JPAINSYMMAN.2005.01.012
Guillermo Luis Lerzo, Julia Revnic, Donald Taylor, Lukas Radbruch, Luis M. Torres, John E. Ellershaw, Antonio Gatti, Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain Supportive Care in Cancer. ,vol. 20, pp. 565- 573 ,(2012) , 10.1007/S00520-011-1124-X
Paul H. Coluzzi, Lee Schwartzberg, John D. Conroy, Steve Charapata, Mason Gay, Michael A. Busch, Jana Chavez, Jeri Ashley, Dixie Lebo, Maureen McCracken, Russell K. Portenoy, Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. ,vol. 91, pp. 123- 130 ,(2001) , 10.1016/S0304-3959(00)00427-9
Rene Fernando Rodriguez, Luis Eduardo Bravo, Fernando Castro, Olga Montoya, Javier Mauricio Castillo, María Pilar Castillo, Paola Daza, José Manuel Restrepo, Mario Fernando Rodriguez, Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. Journal of Palliative Medicine. ,vol. 10, pp. 56- 60 ,(2007) , 10.1089/JPM.2006.0117
Robert B. Raffa, Joseph V. Pergolizzi, Opioid Formulations Designed to Resist/Deter Abuse Drugs. ,vol. 70, pp. 1657- 1675 ,(2010) , 10.2165/11537940-000000000-00000